MoonLake, based in Zug, Switzerland, is a clinical-stage biotech firm focused on advancing next-generation immunotherapies. PHILADELPHIA, Dec. 11, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period"). Investor Deadline: Investors who purchased ...

Core Viewpoint - A class action lawsuit has been filed against Jayud Global Logistics Limited for allegedly engaging in a fraudulent "pump-and-dump" scheme that led to significant stock price manipulation and investor losses during the specified Class Period [1][3]. Company Overview - Jayud Global Logistics Limited, headquartered in Shenzhen, China, offers global cross-border supply chain solutions, including freight forwarding, supply chain management, customs brokerage, and logistics IT systems [2]. Stock Performance and Allegations - During the Class Period from April 21, 2023, to April 30, 2025, Jayud's stock price surged from approximately $1.00 to an all-time high near $8.00, despite a lack of fundamental business news [3]. - The lawsuit claims that this price increase was artificially driven by insiders or affiliates coordinating share dumping through offshore or nominee accounts, culminating in a stock collapse of about 95% on April 2, 2025 [3].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for allegedly misrepresenting its product performance and integrity, leading to investor losses during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Stride securities from October 22, 2024, to October 28, 2025 [1][2]. - Investors have until January 12, 2026, to seek appointment as lead plaintiff representatives [2]. - Allegations include overstating enrollment figures, reducing staff costs beyond legal limits, failing to meet compliance standards, and losing key enrollments [3]. Group 2: Company Background - Stride, Inc. is an education technology company based in Reston, Virginia, providing digital learning programs and instructional support to public and private schools [2]. - The company assured investors of its commitment to personalized learning while allegedly failing to deliver on these promises [3].

PHILADELPHIA, Dec. 9, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to be appointed as a lead ...

Core Viewpoint - A class action lawsuit has been filed against Fiserv, Inc. on behalf of investors who purchased shares during the specified class period, alleging misleading statements regarding the company's guidance and performance [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Fiserv revised its 2025 guidance in July 2025, indicating that while some initiatives were delayed, they were fundamentally sound [3]. - On October 29, 2025, Fiserv admitted that its July guidance was based on assumptions that were difficult to achieve, leading to a significant drop in share value [3]. - Following the acknowledgment of these misleading statements, Fiserv shares fell by 44%, from $126.17 on October 28, 2025, to $70.60 on October 29, 2025 [3]. Group 2: Investor Information - Investors who purchased Fiserv securities during the class period have until January 5, 2026, to seek appointment as lead plaintiff representatives [2]. - The law firm Berger Montague is handling the case and provides contact information for investors seeking more details [4][6]. Group 3: Company Background - Fiserv is a global payments and financial technology company headquartered in Milwaukee, Wisconsin [2]. - Berger Montague, the law firm involved, is recognized for its expertise in complex civil litigation and has recovered over $50 billion for clients over its 55-year history [5].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc for allegedly misleading investors regarding the performance of its North America Fiber Cement segment during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC on behalf of investors who purchased James Hardie common stock or American Depositary Shares from May 20, 2025, to August 18, 2025 [1][2]. - Investors have until December 23, 2025, to seek appointment as lead plaintiff representatives of the class [2]. Group 2: Allegations Against James Hardie - The complaint claims that James Hardie misrepresented the strength of its core North America Fiber Cement segment, stating that demand was strong and inventory levels were normal, despite knowledge of distributors destocking inventory by April and early May 2025 [3]. - On August 19, 2025, James Hardie disclosed a 12% decline in the segment, attributing it to "normalization of channel inventories" and warned of ongoing weakness, leading to a stock price drop of over 34% [4].

Core Viewpoint - A class action lawsuit has been filed against StubHub Holdings, Inc. on behalf of investors who acquired StubHub securities during the specified Class Period, alleging undisclosed issues related to the company's IPO [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who purchased StubHub securities from September 14, 2025, to November 24, 2025, including shares from the September 2025 IPO [1][2]. - Investors have until January 23, 2026, to seek appointment as lead plaintiff representatives of the class [2]. Group 2: Allegations Against StubHub - The complaint claims that StubHub's IPO Registration Statement failed to disclose significant changes in the timing of payments to vendors, which adversely affected the company's free cash flow [3].

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy of its lead product candidate, nimacimab, during the class period from November 4, 2024, to October 3, 2025 [1] Company Overview - Skye Bioscience, Inc. is a clinical-stage biotechnology company based in San Diego, focusing on developing treatments for obesity and metabolic diseases [1] Legal Proceedings - The lawsuit claims that Skye failed to disclose that the efficacy of nimacimab was lower than represented, leading to an overstatement of the drug's clinical and commercial potential [1] - Investors who purchased Skye securities during the class period have until January 16, 2026, to seek appointment as lead plaintiff [1] Stock Performance - Following the announcement of topline data from a Phase 2a study on October 6, 2025, which revealed that the primary endpoint of an 8% weight loss difference compared to placebo was not met, Skye's stock price fell by $2.85 per share, or 60%, closing at $1.90 [1]

Core Viewpoint - A class action lawsuit has been filed against Six Flags Entertainment Corp. on behalf of investors who acquired shares during the period from July 1, 2024, to November 5, 2025, particularly related to the merger with Cedar Fair L.P. [1][3] Summary by Sections Lawsuit Details - The lawsuit claims that the merger registration statement and prospectus did not accurately reflect Six Flags' financial and operational status, highlighting years of underinvestment that necessitated significant capital for the parks to remain competitive [3] Stock Performance - Following the merger closing on July 1, 2024, Six Flags' stock price fell from above $55 per share to as low as $20, representing a 64% decline in value [4] Investor Information - Investors who purchased Six Flags securities during the class period have until January 5, 2026, to seek appointment as lead plaintiff representatives [2]

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc, alleging that the company overstated demand in its North American Fiber Cement segment and downplayed distributor destocking during the Class Period from May 20, 2025, to August 18, 2025, leading to significant investor losses when the company reported a 12% drop in segment sales on August 19, 2025, resulting in a stock price decline of over 34% [1][3]. Company Overview - James Hardie Industries plc is a global building materials company specializing in fiber cement products, with its headquarters located in Dublin, Ireland [2]. Legal Proceedings - Investors who purchased James Hardie securities during the Class Period have until December 23, 2025, to seek appointment as lead plaintiff representatives of the class [2]. Financial Impact - The lawsuit claims that the company's misrepresentation of demand and inventory issues led to a significant stock price drop, causing substantial losses for investors [3].